


IDS/#2
9/6/01

PATENT

IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE



Applicant(s):)	"EXPRESS MAIL" mailing label
)	No. EL 827656769 US
Aguzzi et al.)	
)	Date of Deposit: July 5, 2001
Serial No.: _____ a Rule 1.53(b))	
Continuation of Serial No. 09/407,667)	I hereby certify that this paper
filed September 28, 1999)	(or fee) is being deposited with
)	the United States Postal
Filed: Herewith)	Service "EXPRESS MAIL
)	POST OFFICE TO
For: Prion-Binding Activity in Serum)	ADDRESSEE" service under 37
and Plasma)	C.F.R. §1.10 on the date
)	indicated above and is
Attorney Docket No.: 30187/37578)	addressed to the Commissioner
)	for Patents, Washington, D.C.
Group Art Unit: 1653)	20231.
)	
Examiner: Carlson)	Richard Zimmermann

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

The patents and/or publications listed on the enclosed PTO Form-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the patents or publications are enclosed as necessary.

TIME OF FILING

This information disclosure statement is being filed:

- ☒ 1. with the application or within three months of the filing date of the application or date of entry into the national stage of an international application or, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last. In accordance with 37 CFR §1.97(b), no certification or fee is required.
- ☐ 2. after the time period specified in paragraph 1 above, but, to the best of the undersigned's knowledge, before the mailing date of a final action under 37 CFR §1.113 or notice of allowance under 37 CFR §1.311. Therefore, in accordance with 37 CFR §1.97(c), submitted herewith is:
 - (check either A or B below)**
 - A. ☐ a certification as specified in 37 CFR §1.97(e).
 - B. ☐ the fee set forth in 37 CFR §1.17(p) for submission of an information disclosure statement under 37 CFR §1.97(c).
- ☐ 3. after the mailing date of either a final action under 37 CFR §1.113 or a notice of allowance under 37 CFR §1.311, whichever occurs first, but before payment of the issue fee. Therefore, Applicant submits herewith:
 - A. a certification as specified in 37 CFR §1.97(e);
 - B. the petition fee set forth in 37 CFR §1.17(i); and
 - C. the accompanying petition under 37 CFR §1.97(d).

CERTIFICATION

(only used if No. 2 or No. 3 above is checked)

The person(s) signing below certify

(check appropriate paragraph)

- ☐ that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 CFR §1.97(e)(1).

OR

- ☐ that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement. 37 CFR §1.97(e)(2).

PETITION

(only used if No. 3 above is checked)

- ☐ Applicant(s) hereby petition(s) pursuant to 37 C.F.R. § 1.97(d) that this Information Disclosure Statement, Form PTO-1449, and document(s) identified therein be considered.

PRIOR AND RELATED APPLICATIONS

In accordance with 37 CFR §1.98(d), copies of the patents and publications listed on the enclosed PTO Form-1449 are not provided because the patents and publications were previously cited by, or submitted to, the Patent Office in a prior application that Applicant(s) rely upon for an earlier filing date under 35 U.S.C. §120. Documents listed on the attached Form PTO-1449 were cited by, or submitted to, the examiner of the following patent application(s):

Applicant(s): Aguzzi et al.
Serial No. 09/407,667
Filing Date: September 28, 1999
Title: Prion-Binding Activity in Serum and Plasma
Status: Pending

METHOD OF PAYMENT


- ☒ No fee is required.
- ☐ Attached is a check in the amount of \$_____.

The Commissioner is authorized to charge any fee deficiency required by this paper, or credit any overpayment, to Deposit Account No. 13-2855. A copy of this paper is enclosed.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By: _____


Jeffrey S. Sharp
Reg. No: 31,879

July 5, 2001

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
30187/37578Serial No.
Not AssignedApplicant
Aguzzi et al.Filing Date
HerewithGroup
1653**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

10/26 U.S. PTO
09/899407
67766701**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Carpenter et al., "Characterization of two patched receptors for the vertebrate hedgehog protein family," <i>Proc. Natl. Acad. Sci. USA</i> , 95:13630-13634 (1998)
	C2	Carstea et al., "Niemann-Pick C1 Disease Gene: Homology to Mediators of Cholesterol Homeostatis," <i>Science</i> , 277:228-231 (1997)
	C3	Loftus, "Murine Model of Niemann-Pick C Disease: Mutation in a Cholesterol Homeostatis Gene", <i>Science</i> , 277:232-235 (1997)
	C4	Porter et al., "Cholesterol Modification of Hedgehog Signaling Proteins in Animal Development," <i>Science</i> , 274:255-259 (1996)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

30187/37578

Serial No.

Not Assigned

INFORMATION DISCLOSURE STATEMENT*(Use several sheets if necessary)*

Applicant

Aguzzi et al.

Filing Date

Herewith

Group

1653

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C5

The et al., "Hedgehog Movement Is Regulated through *tout velu*-Dependent Synthesis of a Heparan Sulfate Proteoglycan," *Molecular Cell*, 4:633-639 (1999)

C6

Williams et al., "Functional antagonists of sonic hedgehog reveal the importance of the N terminus for activity," *Journal of Cell Science*, 112:4405-4414 (1999)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.